way 100135 has been researched along with am-356 in 1 studies
| Studies (way 100135) | Trials (way 100135) | Recent Studies (post-2010) (way 100135) | Studies (am-356) | Trials (am-356) | Recent Studies (post-2010) (am-356) |
|---|---|---|---|---|---|
| 143 | 0 | 34 | 216 | 0 | 42 |
| Protein | Taxonomy | way 100135 (IC50) | am-356 (IC50) |
|---|---|---|---|
| Potassium channel subfamily K member 3 | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Egashira, N; Fujiwara, M; Hayakawa, K; Ikeda, T; Iwasaki, K; Mishima, K | 1 |
1 other study(ies) available for way 100135 and am-356
| Article | Year |
|---|---|
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.
Topics: Animals; Arachidonic Acids; Cannabidiol; Cerebral Infarction; Cerebrovascular Circulation; Endocannabinoids; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperazines; Polyunsaturated Alkamides; Receptor, Serotonin, 5-HT1A; Resorcinols; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists | 2005 |